101 OXANDROLONE INCREASED FINAL HEIGHT IN TURNER'S SYNDROME (TS)

Abstract

29 pat. with TS were-studied: 20 pat. with 45,XO karyotyping (group I): mean chronol. age (CA) 14.1 ± 0.5 (SEM), bone age (BA) 11.1 ± 0.3 yrs., 9 pat. were mosaics (group II): mean CA 14.2 ± 0.6, BA 12.0 + 0.4 yrs. Oxandrolone dosage was 0.1 mg/kg/day, treatment period was 1 t o 6 years.In group I pretreatment growth velocity (GV) 2.8 ± 0.3 increased to 5.3 ± 0.3 and 5.0 ± 0.3 cm/yr. during first and second 6 months of therapy (TH). Afterwards GV slowly declined to 2.1 ± 0.4 after 5 yrs. of TH. BA velocity was 0.71 ± 0.1 “yrs.”/yr. during first year of TH, declining to 0.21 ± 0.07 at 5 yrs. of TH. Pretreatment height age/BA ratio 0.86 ± 0.02 was increased to 0.92. Pretreatment height standard deviation score (SDS) for CA −3.34 ± 0.17 was reduced to −2.63 ± 0.41 at 5 yrs. of TH, pretreatment height SDS for BA −1.39 ± 0.17 was diminished to −1.02 ± 0.32. In 11 of 20 pat. TH was finished after 4.0 years (1.5 − 6.0):CA 18.1 ± 0.4, BA 13.4 ± 0.1 yrs., height 149.2 cm (143.4 − 155.5 cm), height SDS (CA) −2.17 ± 0.19. In 6 of these 11 pat. height was above 150 cm. Similar but less pronounced results were found in group II. - There was a significant negative correlation between pretreatment BA and GV under oxandrolone in all TS pat. (r= -0.61, p < 0.001). - Side effects: In 6 of 29 pat. a small transient increase in transarninases.Thus, oxandrolone improved final height in many pat. with TS.